Rocket Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2019. Rocket is a clinical-stage biotechnology company developing gene therapies for rare diseases; it has no approved products and has generated no revenue.
Financial performance and position
| Metric | Q3 2019 | Q3 2018 | Nine months 2019 | Nine months 2018 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $14.8m | $13.1m | $44.0m | $29.6m |
| General and administrative expense | $4.3m | $2.3m | $12.5m | $15.0m |
| Net loss | $19.3m | $16.1m | $57.4m | $47.2m |
| Loss per share, basic and diluted | $0.38 | $0.40 | $1.19 | $1.22 |
Margins: Not meaningful because the company had no revenue. Q3 operating expenses rose $3.8m year over year. Nine-month R&D rose $14.4m, primarily from manufacturing and process development, clinical trials, research agreements, licensing, and increased R&D staffing. Nine-month G&A fell $2.5m; 2018 included $5.3m of nonrecurring merger-related costs.
- Liquidity at September 30: Cash and cash equivalents were $89.2m and investments were $151.4m, totaling $240.6m. Current assets were $245.6m and current liabilities were $22.2m.
- Cash flows, nine months: Operating activities used $44.9m, versus $33.0m in 2018; investing activities used $62.5m, including $14.0m of property and equipment purchases; financing provided $85.4m, mainly from the stock offering.
- Debt: Convertible notes have $52.0m principal, a $44.1m carrying value, 5.75% stated interest, 15.3% effective interest, and mature August 2021. They are unsecured and potentially convertible into approximately 1.62m shares.
- Equity and dilution: The April public offering generated $86.1m net proceeds from 5.175m shares. Common shares outstanding were 50.38m at September 30, compared with 45.19m at December 31, 2018.
Material changes and business developments
- Q3 net loss increased $3.2m year over year; higher R&D and G&A costs were partly offset by higher interest and investment income.
- Nine-month net loss increased $10.2m, reflecting substantially higher R&D spending, partly offset by lower G&A and other expense.
- Rocket received FDA IND clearance for its PKD program in Q3 2019. The first patient in the LAD-I Phase 1/2 trial was dosed in Q3; the first Danon patient had been dosed in Q2.
- The company reported FDA alignment on the RP-L102 Fanconi anemia Phase 2 design and primary endpoint. The filing describes enrollment as ongoing and dosing as anticipated in Q4 2019.
Outlook, risks and contingencies
- Management expects the $240.6m of cash, cash equivalents and investments to fund operating expenses and capital expenditure requirements into the first half of 2021. It expects spending and operating losses to increase as clinical development, manufacturing, and facilities work expand.
- Stated development expectations included preliminary data from the first two RP-L102 Process B patients in Q4 2019; initial LAD-I Phase 1 data in Q4; preliminary PKD data in 2020; Danon Phase 1 data in 2020; and an IMO IND filing in 2020. These are forward-looking expectations, not assured outcomes.
- Key risks include clinical safety or efficacy setbacks, slow enrollment, regulatory delays or additional study requirements, manufacturing and supply constraints, reliance on third parties, intellectual-property and licensing disputes, and the need for future financing. Additional equity financing could dilute shareholders; other funding arrangements could require surrendering rights.
- The company reported no litigation it expected to have a material adverse effect. It disclosed a 15-year New Jersey facility lease with estimated commitments of approximately $29.3m; the lease had not commenced as of September 30 because landlord improvements were incomplete. The filing also presents $31.1m in future minimum lease-payment commitments, including that lease.
- A $6.5m CIRM grant supports LAD-I development; grant proceeds are recognized as eligible costs are incurred. The filing reported $0.4m of grant-related receivable and R&D expense reduction for Q3.
Important facts for investors to verify
- Whether trial enrollment, dosing, and reported data timelines were achieved, and how subsequent safety and efficacy results compare with the filing’s expectations.
- Whether spending and cash burn remain consistent with management’s stated runway into the first half of 2021, including the impact of facility construction and clinical manufacturing.
- The terms, conversion or repayment prospects of the 2021 notes, and potential dilution from options and other equity-linked securities.
- Progress toward the expected $6.5m CIRM grant funding and the timing and cost of the New Jersey facility lease commencement.
- The filing reports effective disclosure controls, but management’s conclusion provides reasonable—not absolute—assurance; review subsequent filings for changes in controls, financing needs, and risk disclosures.